---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055622"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T15:02:22.643113+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MannKind Q1 revenue $66M (+63% YoY); net income $11M; FDA Fast Track for MNKD-101

## Summary
- Total revenues $66.3M (+63% YoY); GAAP net income $11M; non-GAAP net income $15M.
- Tyvaso DPI royalties surged 94% to $22.7M; collaborations & services revenue up 118% to $24.8M.
- Afrezza net revenue $14.4M (+16%); V-Go down 16% to $4.3M.
- Cash and investments $304.5M; repaid ~$37M of secured debt in early April.
- FDA Fast Track and IND clearance for MNKD-101 (clofazimine inhaled suspension).

## SEC filing metadata
- accession: 0000950170-24-055622
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000095017024055622/0000950170-24-055622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000095017024055622/mnkd-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055622
- JSON: https://secwatch.observer/filing/0000950170-24-055622.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055622.txt

## Source-grounded claims
- claim_id: 0cb533edb8f430dafa7af63d5ce2770876b78f04
  claim: MANNKIND CORP reported the quarter ended March 31, 2024 results: revenue Total revenues of $66M, net income Net income of $11M.
  evidence_excerpt: CORPORATION REPORTS 2024 FIRST QUARTER FINANCIAL RESULTS: PROVIDES CLINICAL DEVELOPMENT UPDATE Conference Call to Begin Today at 5:00 p.m. (ET) • 1Q 2024 Total revenues of $66M; +63% vs. 1Q 2023 • 1Q 2024 Net income of $11M; Non-GAAP net income of $15M • $304M of cash and cash equivalents and investments at March 31, 2024 • In early April, repaid
  evidence_url: https://www.sec.gov/Archives/edgar/data/899460/000095017024055622/0000950170-24-055622-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.